Business
Result of 2020 Annual General Meeting
Result of 2020 Annual General Meeting.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3702X\n Angle PLC\n 27 August 2020\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 27 August 2020\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n Result of 2020 Annual General Meeting\n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.\n \n \n \n \n \n \n \n \n For further information ANGLE:\n \n \n \n \n \n \n \n \n ANGLE plc\n \n \n \n \n +44 (0) 1483 343434\n \n \n \n \n \n \n Andrew Newland, Chief Executive\n \n \n Ian Griffiths, Finance Director\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap Ltd (NOMAD and Joint Broker)\n \n \n Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith\n \n \n ECM - Alice Lane, Sunila de Silva\n \n \n \n \n \n \n \n +44 (0)20 7220 0500\n \n \n \n \n \n \n WG Partners (Joint Broker)\n \n \n Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee \n \n \n \n \n \n \n \n +44 (0) 203 705 9330\n \n \n \n \n \n \n \n \n \n \n \n \n FTI Consulting\n \n \n Simon Conway, Ciara Martin, Sam Purewal\n \n \n Matthew Ventimiglia (US) \n \n \n \n \n \n \n \n +44 (0) 203 727 1000\n \n \n +1 212 850 5624\n \n \n \n \n \n \n \n \n \n \n \n \n About ANGLE plc \n \n \n www.angleplc.com\n \n \n \n \n ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.\n \n \n \n \n \n ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen as being a complete cell they allow DNA, RNA...